Avantor, Inc.

Listed Company

AVTRCIK 0001722482NYSELarge AcceleratedLaboratory Analytical InstrumentsFY ends Dec 31

Period

FY 2025

Revenue

$6.55B

Net Income

$-530.20M

Total Assets

$11.79B

Equity

$5.57B

Shares Out

682.76M

Op. Cash Flow

$623.80M

Business

Avantor, Inc. is a leading global provider of mission‑critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries, supporting customers from discovery through scale‑up and manufacturing. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement, including high‑purity chemicals, specialized silicones, single‑use assemblies, analytical kits, instruments and onsite lab and production services. The company reports two business segments: Laboratory Solutions and Bioscience Production. It serves customers across the Americas, Europe and AMEA via a global sales force, e‑commerce platforms, targeted catalogs and a worldwide distribution and manufacturing network.

Summary from filing dated 2025-02-07

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	6,552	6,784	6,967	7,512	7,386
Cost of sales	4,413	4,504	4,603	4,910	4,883
Gross profit	2,139	2,279	2,364	2,603	2,503
Selling, general and administrative expenses	1,596	1,641	1,507	1,473	1,531
Impairment charges	785	0	161	0	0
Gain on sale of business	5	−447	0	0	—
Operating (loss) income	−246	1,085	696	1,130	972
Interest expense, net	−170	−219	−285	−266	—
Loss on extinguishment of debt	−5	−11	−7	−13	−12
Other (expense) income, net	−21	−1	6	−800,000	11
(Loss) income before income taxes	−441	854	411	851	753
Income tax expense	−89	−142	−89	−165	−180
Net (loss) income	−530	712	321	687	573
Basic (in dollars per share)	−0.78	1.05	0.48	1.02	0.86
Diluted Basic (in dollars per share)	−0.78	1.04	0.47	1.01	0.85
Basic (in shares)	681	680	676	651	591
Diluted (in shares)	681	682	678	679	600

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	365	262	263	373	302
Accounts receivable, net of allowances of $29.6 and $30.2	1,075	1,035	1,150	1,218	1,222
Inventory	818	732	828	914	872
Other current assets	193	119	144	153	81
Total current assets	2,451	2,147	2,385	2,658	2,477
Property, plant and equipment, net (see note 10)	767	708	738	727	706
Other intangible assets, net (see note 11)	3,194	3,360	3,775	4,133	5,140
Goodwill, net (see note 11)	4,987	5,539	5,717	5,653	5,341
Other assets	396	360	358	294	233
Total assets	11,795	12,115	12,973	13,464	13,897
Current portion of debt	31	821	260	364	45
Accounts payable	742	663	626	758	755
Employee-related liabilities	163	168	133	122	200
Accrued interest	47	49	50	50	50
Other current liabilities	396	307	411	364	401
Total current liabilities	1,379	2,008	1,480	1,659	1,451
Debt, net of current portion	3,916	3,235	5,277	5,923	6,978
Deferred income tax liabilities	557	557	613	731	913
Other liabilities	378	358	350	295	358
Total liabilities	6,230	6,158	7,720	8,609	9,700
Commitments and contingencies (see note 13)	—	—	—	—	—
Common stock including paid-in capital, 682.0 and 680.8 shares issued and outstanding	3,985	3,938	3,830	3,785	2,753
Treasury stock at cost, 6.6 and 0.0 shares	−76	0	—	—	—
Accumulated earnings	1,673	2,203	1,492	1,170	484
Accumulated other comprehensive loss	−17	−184	−69	−100	−43
Total stockholders equity	5,565	5,957	5,253	4,855	4,197
Total liabilities and stockholders equity	11,795	12,115	12,973	13,464	13,897

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Amortization	410	406	402	406	379
Stock-based compensation expense	46	47	41	46	51
Non-cash restructuring charges (see note 12)	3	17	0	0	—
Provision for accounts receivable and inventory	64	75	85	65	45
Deferred income tax expense (benefit)	8	−47	−172	−69	−18
Amortization of deferred financing costs	9	11	13	16	16
Foreign currency remeasurement loss (gain)	2	−300,000	−3	10	7
Pension termination charges	18	9	0	0	—
Accounts receivable	14	46	77	−45	−112
Inventory	−109	−19	30	−113	−130
Accounts payable	42	60	−140	16	65
Accrued interest	−1	−2	300,000	100,000	5
Other assets and liabilities	−144	−38	49	−179	57
Other	−1	−300,000	−700,000	−7	3
Net cash provided by operating activities	624	841	870	844	954
Capital expenditures	−129	−149	−146	−133	−111
Proceeds from sale of disposal group, net of cash sold	0	585	0	0	—
Other	−2	3	3	2	4
Net cash (used in) provided by investing activities	−131	439	−144	−110	−4,122
Debt borrowings	1,108	0	0	327	2,835
Debt repayments	−1,426	−1,342	−846	−947	−534
Payments of debt refinancing fees	−15	0	−2	−600,000	−41
Proceeds received from exercise of stock options	5	69	18	17	83
Proceeds received from exercise of stock options	−6	−9	−14	—	—
Payments for repurchase of common stock	−75	0	0	—	—
Net cash used in financing activities	−409	−1,281	−844	−649	3,219
Effect of currency rate changes on cash and cash equivalents	20	−22	8	−16	−13
Net change in cash, cash equivalents and restricted cash	104	−23	−109	70	38

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro